Method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists
申请人:——
公开号:US20020137746A1
公开(公告)日:2002-09-26
This invention encompasses a method of treating or preventing urinary incontinence in a mammalian patient comprising administering to the patient a compound of formula I:
1
or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses certain pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases comprising the use of compounds of formula I.
CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
申请人:MERCK FROSST CANADA & CO.
公开号:EP1216238B1
公开(公告)日:2004-02-18
US6369084B1
申请人:——
公开号:US6369084B1
公开(公告)日:2002-04-09
[EN] CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT<br/>[FR] ACIDES CARBOXYLIQUES ET ACYLSULFONAMIDES, COMPOSITIONS CONTENANT DE TELS COMPOSES ET METHODES DE TRAITEMENT
申请人:MERCK FROSST CANADA INC
公开号:WO2001019814A2
公开(公告)日:2001-03-22
This invention encompasses the novel compounds of formula (A), which are useful in the treatment of prostaglandin mediated diseases, or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses certain pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases comprising the use of compounds of formula (A).
Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
申请人:Merck Frosst Canada & Co.
公开号:US06369084B1
公开(公告)日:2002-04-09
This invention encompasses the novel compounds of formula A, which are useful in the treatment of prostaglandin mediated diseases,
or a pharmaceutically acceptable salt, hydrate or ester thereof. The invention also encompasses certain pharmaceutical compositions and methods for treatment of prostaglandin mediated diseases comprising the use of compounds of formula A.